Evidence map›Paper›PMID 31854465›Full record

Trial reportMovement disorders : official journal of the Movement Disorder Society2020

Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.

Robert L White, Meghan C Campbell, Dake Yang, William Shannon, Abraham Z Snyder, Joel S Perlmutter

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Movement disorders : official journal of the Movement Disorder Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Resting-State Functional Connectivity Predicts STN DBS Clinical Response.Movement disorders : official journal of the Movement Disorder Society · 2021
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Robert L WhiteDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-4030-4290
Meghan C CampbellDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Dake YangBioRankings, St. Louis, Missouri, USA.
William ShannonBioRankings, St. Louis, Missouri, USA.
Abraham Z SnyderDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Joel S PerlmutterDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Washington University in St. Louis · USBioRankings (United States) · US

Funding

INVESTIGATIONS OF DEMENTIA IN PARKINSON DISEASER01NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2011 to 2021
$8.2M
Parkinson Disease Clinical Subtypes: Validation, Clinical Utility, and Biological CorrelatesR01NS097437 · NINDS · WASHINGTON UNIVERSITY · PI MEGHAN C CAMPBELL · 2017 to 2026
$4.1M
Investigations of Dementia in Parkinson DiseaseRF1NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2023 to 2023
$2.3M
NINDS NIH HHS R01 NS075321NINDS NIH HHS R01 NS097437NINDS NIH HHS RF1 NS075321
6 · The paper itself

Abstract

objectiveThe objective of this study was to investigate the effects of levodopa on functional brain networks in Parkinson's disease.

methodsWe acquired resting state functional magnetic resonance imaging in 30 drug-naïve participants with Parkinson's disease and 20 age-matched healthy controls. Each participant was studied following administration of a single oral dose of either levodopa or placebo in a randomized, double-blind, crossover design.

resultsThe greatest observed differences in functional connectivity were between Parkinson's disease versus control participants, independent of pharmacologic intervention. By contrast, the effects of levodopa were much smaller and detectable only in the Parkinson's disease group. Moreover, although levodopa administration in the Parkinson's disease group measurably improved motor performance, it did not increase the similarity of functional connectivity in Parkinson's disease to the control group.

conclusionsWe found that a single, small dose of levodopa did not normalize functional connectivity in drug-naïve Parkinson's disease. © 2019 International Parkinson and Movement Disorder Society.

Indexed as

Parkinson DiseasePharmaceutical PreparationsAntiparkinson AgentsBrainHumansLevodopaMagnetic Resonance ImagingAntiparkinson AgentsLevodopaPharmaceutical Preparationsdrug naivefMRIlevodopaParkinson's diseaseresting-state functional connectivity

Identifiers

PMID31854465
PMCPMC7138409
OpenAlexW2996303304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.